The U.S. Food and Drug Administration has approved a three-drug regimen to treat complicated urinary tract infections and complicated intra-abdominal infections, both of which can be especially problematic for people living with HIV.
"We're very much putting the patient in the driver's seat," said Heather Alt, deputy director of nursing with Whitman-Walker. "If folks didn't feel ready, we would not push them to start."
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Sixteen years after the success of Project START for HIV risk reduction, we still don't know what works best for helping people with HIV stay in care after prison.
Despite rising HIV rates and structural barriers to accessing care, American Indians and Alaska Natives do not have worse clinical outcomes when they're in care.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
People newly diagnosed with HIV must be able to access treatment and support, which could be improved if guided by people who have been taken the test themselves, researchers found.
Study results of an intervention that includes a custom smartphone app tailored to the needs and preferences of a rural population of people with HIV living in the southern U.S.